Anti-EGFR-Based Therapy in Recurrent or Metastatic HNSCC - What Difference Does it Make?
Cancer Invest
; 41(1): 93-100, 2023 Jan.
Article
en En
| MEDLINE
| ID: mdl-36239419
ABSTRACT
Patients with R/M HNSCC treated with palliative first-line therapy at Hannover Medical School between October 2005 and December 2016 have been included to show changes in survival following broad utilization of cetuximab. Treatment periods were defined from 10/2005 to 12/2008 (Period A) and 01/2009 to 12/2016. Overall survival did not improve over time. However, in subgroup analysis cetuximab utilized at any time vs. never showed a significant improve of overall survival (11.3 vs. 6.3 months, HR 0.55, 95%-CI 0.4-0.8, p = 0.04). Therefore, this study supports the application of cetuximab in this real-world population.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias de Cabeza y Cuello
Límite:
Humans
Idioma:
En
Revista:
Cancer Invest
Año:
2023
Tipo del documento:
Article
País de afiliación:
Alemania